Cyteir Therapeutics Inc

NASDAQ CYT

Data sourced from

and

Download Data

Cyteir Therapeutics Inc Depreciation and Amortization for the Trailing 12 Months (TTM) ending September 30, 2023: USD 538.00 K

Cyteir Therapeutics Inc Depreciation and Amortization is USD 538.00 K for the Trailing 12 Months (TTM) ending September 30, 2023, a -15.67% change year over year. Depreciation and Amortization involve the systematic allocation of the cost of tangible and intangible assets over their useful lives.

Cyteir Therapeutics Inc Depreciation and Amortization for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 638.00 K, a 47.00% change year over year.
Cyteir Therapeutics Inc Depreciation and Amortization for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 434.00 K, a 69.53% change year over year.
Cyteir Therapeutics Inc Depreciation and Amortization for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 256.00 K.

NASDAQ: CYT

Cyteir Therapeutics Inc

CEO	Mr. Joseph S. Zakrzewski
IPO Date	June 18, 2021
Location	United States
Headquarters	128 Spring Street, Lexington, MA, United States, 02421
Employees	46
Sector	Healthcare
Industry	Biotechnology

Description

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.

Key trends